As of March 31, 2024, MoonLake held cash, cash equivalents and short-term marketable debt securities of $547.1 million.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
- 3 Best Stocks to Buy Now, 4/29/2024, According to Top Analysts
- 3 Best Stocks to Buy Now, 4/24/2024, According to Top Analysts
- MoonLake Immunotherapeutics enters three-year partnership with Komodo Health
- Estee Lauder upgraded, Petco downgraded: Wall Street’s top analyst calls
Questions or Comments about the article? Write to editor@tipranks.com